Impact of Oral versus Intravenous Ibuprofen on Neurodevelopmental Outcome: A Randomized Controlled Parallel Study

Abstract

Objective Although neurodevelopmental outcomes related to the management of patent ductus arteriosus with intravenous indomethacin and ibuprofen are known, little data on the long-term effects of oral ibuprofen can be found in the literature.

Method A follow-up study of 99 infants with birth weight ≤ 1,500 g and gestational age ≤ 32 weeks who received either oral or intravenous ibuprofen for patent ductus arteriosus was conducted to assess at 18 to 24 months (corrected age), abnormal neurological, neurosensory, and cognitive impairment were defined as follows:neurological outcomes included moderate/severe cerebral palsy, neurosensory outcomes included bilateral hearing loss and blindness in either eye, and cognitive impairment included mental developmental index score < 70.

Results The 18- to 24-month (corrected age) long-term outcomes of 30 subjects who received oral ibuprofen were compared with 27 subjects who received intravenous ibuprofen by certified and experienced examiners who were blind to the definitions of the groups. The results revealed that the long-term outcomes of the treatment regimens did not significantly differ.

Conclusions Preterm infants who were treated with oral ibuprofen for patent ductus arteriosus had similar neurological, neurosensory, and cognitive outcomes to patients who received intravenous ibuprofen at 2 years of age.

Keywords

ibuprofen - long-term outcome - neurodevelopmental outcome - preterm - very low birth weight

• References

• 1 Demirel G, Erdeve O, Dilmen U. Pharmacological management of PDA: oral versus intravenous medications. Curr Clin Pharmacol 2012; 7: 263-270
• 2 Erdeve O, Yurttutan S, Altug N , et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2012; 97: F279-F283
• 3 Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010; 125: 1020-1030
• 4 Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006; 117: 1113-1121
• 5 Skinner J. Diagnosis of patent ductus arteriosus. Semin Neonatol 2001; 6: 49-61
• 6 Van Overmeire B, Chemtob S. The pharmacologic closure of the patent ductus arteriosus. Semin Fetal Neonatal Med 2005; 10: 177-184
• 7 Cherif A, Jabnoun S, Khrouf N. Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants. Am J Perinatol 2007; 24: 339-345
• 8 Gokmen T, Erdeve O, Altug N, Oguz SS, Uras N, Dilmen U. Efficacy and safety of oral versus ıntravenous ıbuprofen in very low birth weight preterm ınfants with patent ductus arteriosus. J Pediatr 2011; 158 (4) 594-54
• 9 Erdeve O, Gokmen T, Altug N, Dilmen U. Oral versus intravenous ibuprofen: which is better in closure of patent ductus arteriosus?. Pediatrics 2009; 123: e763
• 10 Rheinlaender C, Helfenstein D, Pees C , et al. Neurodevelopmental outcome after COX inhibitor treatment for patent ductus arteriosus. Early Hum Dev 2010; 86: 87-92
• 11 André P, Thébaud B, Delavaucoupet J , et al. Late-onset cystic periventricular leukomalacia in premature infants: a threat until term. Am J Perinatol 2001; 18: 79-86
• 12 Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 2007; 119: 1165-1174
• 13 Doyle LW. Victorian Infant Collaborative Study Group. Outcome at 5 years of age of children 23 to 27 weeks' gestation: refining the prognosis. Pediatrics 2001; 108: 134-141
• 14 Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A. Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 2007; 150: 229-234 , e1
• 15 Madan JC, Kendrick D, Hagadorn JI, Frantz III ID. National Institute of Child Health and Human Development Neonatal Research Network. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics 2009; 123: 674-681
• 16 The Victorian Infant Collaborative Study Group. Surgery and the tiny baby: sensorineural outcome at 5 years of age. J Paediatr Child Health 1996; 32: 167-172
• 17 Bayley N. Bayley Scales of Infant Development II. San Antonio, TX: Psychological Corp.; 1993